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MOLECULARLY TARGETED NANOMEDICINE: ROLE OF HSP90 INHIBITOR AND 
SOPHOROLIPIDS IN THE TREATMENT OF LUNG CANCER 
 
 




Lactonic sophorolipids (LSL) are a class of enzymatically modified glycolipids known to have HDAC 
inhibition activity and anticancer properties. Ganetespib (GT), an Hsp90 inhibitor, is known for its 
superior antitumor activity in several K-RAS mutant Non-Small-Cell Lung Cancer (NSCLC) cells. 
In this study, a new anti-oxidant nanoplatform is formulated using the combination of these two 
drugs, LSL and GT, in order to target both HDAC inhibition and Hsp90 signaling pathways in 
NSCLC. Nanoceria (NC) is an excellent redox platform will be specifically used to supplement the 
therapeutic potency of these drugs in the effective treatment of NSCLC. We hypothesized that the 
therapeutic efficacy of GT will be synergistically accelerated by the HDAC inhibition and redox 
activity of LSL and NC, respectively. For this, polyacrylic acid-coated nanoceria (NC-COOH) is 
synthesized using solvent precipitation method and folic acid is conjugated using ‘click’ chemistry 
in order to target NSCLC and to minimize adverse side effects. As a result of combination therapy, 
enhanced ROS production is detected and more than 80% reduction in the cell viability is recorded 
within 24 h of incubation. Migration assays indicated that the highly metastatic nature of NSCLC is 
successfully restricted upon treatment of these drugs-loaded functional nanoceria. In addition, 
various cell-based assays including detection of apoptosis and necrosis, HDAC inhibition, MTT and 
fluorescence microscopy are performed to validate the highly effective combination therapy of 
NSCLC. Together, our results represent for a unique combination of drugs and personalized 
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Histone acetylation and deacetylation plays a crucial role in the regulation of gene 
expression.1 They are balanced by two most important enzymes histone 
acetylases (HAT) and histone deacetylases (HDAC).2-4 Altered expression and 
mutation of genes associated with HDAC are directly linked to cell proliferation and 
tumor development.5,6 Studies have shown that HDAC inhibitors are known to alter 
gene expression and influence on cellular growth arrest, cytotoxicity and induce 
apoptosis.7-12 Thus, the development of HDAC inhibitors, their therapeutic role and 
mechanism of action has received tremendous attention in the field of cancer 
treatment.13,14 Lactonic sophorolipid (LSL) is a glycolipid molecule synthesized 
from specific yeast species.15,16 Many reports are available on the 
immunomodulatory and anti-inflammatory properties of LSL.17-20 However, studies 
have reported on the anticancer activity of LSL on different cell lines including 
pancreatic, esophageal and lung cancer.18-26 It is indicated that one of the 
mechanisms for anti-tumor activity of LSL is the HDAC inhibition, where the histone 
deacetylases are inhibited and interferes with the gene expression.17   
Lung carcinomas are currently the leading cause of cancer-related mortality 
worldwide due to its poor prognosis, multidrug resistance (MDR) and low survival 
rate.27-29 Approximately, more than 85% of lung cancer cases are related to non-
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small-cell lung cancer (NSCLC) and the major histopathological subtypes are 
adenocarcinomas, squamous cell carcinomas and large cell carcinomas.28,30-34 
Oncogenic K-RAS mutations in human NSCLC (10-30%) have gained resistance 
to chemotherapy and radiation.35-37 Although K-RAS mutations are well known, yet 
there is a lack of effective therapeutic options available for K-RAS driven NSCLC.35 
Severe side effects, multidrug resistance and poor survival outcomes are the 
limitations of current NSCLC therapies,38,39 and this is indicative of the urgency in 
the development of an effective chemotherapy for the  treatment of NSCLC. 
Figure 1: Schematic representation of the mechanism of actions of the 
combination of drugs: ganetespib and lactonic sophorolipid for the effective 





Targeted delivery of two or more chemotherapeutic drugs specifically to tumor site 
is becoming a popular choice for the effective treatment of cancer. The 
combination therapy allows inhibition of separate tumorigenesis pathways that 
overcomes severe side effects, multidrug resistance, and have potential to improve 
treatment response. Considering the importance of combination therapy, a new 
drug combination, ganetespib (GT) and LSL is proposed in this study. We 
reasoned that GT is a second generation Hsp90 inhibitor, which leads to the 
degradation of major client proteins. It disrupts important signaling cascades 
responsible for cell proliferation and survival of tumor.40-43 GT is also known to have 
potential antineoplastic activity and shown promising results in the treatment of 
NSCLC in past few years.42,44-47 In addition, the use of nanotechnology-based drug 
delivery system has become an emerging area of interest for better payloads, 
biocompatibility and targeted delivery of chemotherapeutic drugs, which resulted 
in minimal side effects.48-53 Recent studies indicated the huge potential of various 
nanoparticles as drug carriers in cancer therapy, including targeted drug delivery, 
diagnosis, imaging, and treatment.31,54-57 Among others, cerium oxide 
nanoparticles (NC) has received considerable attention due to its excellent 
catalytic and anti-oxidant properties on different cell systems.58-62 As an 
antioxidant, many reports are available indicating its cytotoxic nature towards 
cancer cells, whereas protective effects in certain neurodegenerative disorders.63  
Herein, we report an innovative combination therapy approach for the effective 
treatment of NSCLC (A549 cells). Blend of chemotherapeutic drugs, LSL and GT, 
are encapsulated into the folate-conjugated nanoceria, which minimizes the off-
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target effects of drug combinations. Additionally, the anti-oxidative nature of 
nanoceria facilitates for the survival of healthy tissues, while in situ generation of 
chronic oxidative stress in the tumor cells reduces its viability. This property of NC 
supplements the synergistic therapeutic actions, where LSL plays an important 
role in HDAC inhibition and GT inhibits the Hsp90 signaling pathways towards the 
treatment of NSCLC (Figure 1).64,65 The therapeutic effects of this combination 
therapy are examined by performing various cell-based assays including cell 
viability, enhanced ROS, apoptosis and necrosis, migration and HDAC assays. 
Taken together, findings from this study would provide clinically acceptable strong 
support for the NSCLC treatment decision making and potential translational 







































Results and Discussion 
 
 
Synthesis and Characterizations of poly (acrylic acid) (PAA)-coated Cerium Oxide 
Nanoparticles (PNC): 
Previously reported water-based alkaline precipitation method was used to synthesize 
polyacyrilic acid coated nanoceria (NC-COOH).66 The obtained yellow color solution of 
nanoceria was centrifuged to get rid of agglomerates and bigger size particles and was 
further purified by dialysis technique (MWCO 6-8 kDa) (1, Scheme 1).67 Optical lipophilic 
DiI dye was encapsulated in NC-COOH (encapsulation efficiency, EEDiI = 85%) using 
modified solvent diffusion method. DiI dye is important for optical imaging because of its 
high extinction coefficient (ε > 125000 cm-1 M-1) and higher fluorescence emission (λmax 
= 585 nm) and used as negative optical probe to evaluate the toxicity of carboxylated 
nanoceria. To functionalize our nanoparticles, carboxylic acid groups of NC-COOH (2 X 
10-3 mol) were conjugated with propargylamine (15 X 10-3 mol) using EDC (15 X 10-3 mol) 
and NHS (15 X 10-3 mol) chemistry in the presence of MES buffer (pH = 6.0). In presence 
of CuI catalyst, using click chemistry, folic acid was conjugated on the surface of 
nanoparticles to target lung cancer expressing folate receptors on the surface (4 and 5, 
Scheme 1). Click chemistry is the reaction between folate-azide (2 X 10-2 mol) and triple 
bond of propargylamine (1.5 X 10-3 mol). The prepared folate nanoceria was further 
purified using dialysis technique and then encapsulated with DiI dye via solvent diffusion 
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method, which is used as positive control for targeted delivery of drugs. Encapsulation of 
therapeutic drugs, LSL and GT in folate nanoceria (5, Scheme 1, 1.0 X 10-3 mol, EELSL/GT 
= 75%) using same modified solvent diffusion method was done for therapeutic 
applications. Finally, these preparations were dialyzed for purification and stored at 4° C 
for further characterizations. 
Characterizations of PAA Polymer-Coated Functional Nanoceria. 
The synthesized NC-COOH was characterized by FT-IR spectroscopy (Figure 2) to 
confirm the presence of carboxyl groups on the surface as an indication of successful 
coating of polyacyrilic acid. The presence of a carboxyl stretching band at 1685 cm-1 
confirmed the presence of C = O stretching indicating the successful coating of PAA 
polymer on nanoceria. PAA coating makes our nanoparticle sable, compatible and allows 
efficient encapsulation of drugs. The carboxyl groups on the surface allow conjugation of 
various functional groups for targeted delivery. Dynamic light scattering studies showed 
the presence of monodisperse nanoceria preparation with an average hydrodynamic 
diameter of 56.75 ± 2 nm (Figure 2B). The overall surface charge of the different 
functional nanoceria preparations was assessed by ζ potential and was found to be -25.6 





Figure 2: The presence of PAA coating in NC was confirmed by the presence of acid 
carbonyl band at 1685 cm-1 in FT-IR spectrum. Determination of the size of NPs using 
dynamic light scattering (DLS) showing the average hydrodynamic diameter of 56.75 nm. 
Conjugation of folic acid on the surface of nanoceria and successful encapsulation of 
optical DiI dye in the polymer coating was confirmed by UV-Vis absorbance and 
fluorescence spectroscopy using a high–throughput plate reader. The absorbance 
spectrum of DiI encapsulating folate nanoceria (Figure 3E) confirmed the presence of 
both DiI dye (λabs = 585 nm) and folic acid (λabs = 360 nm). This was further confirmed by 
their corresponding fluorescence spectra (Fol: λem = 460 nm; DiI: λem = 600 nm, Figure 
3D and 3F). The size and fluorescence of these nanoceria preparations were remained 




Scheme 1: Schematic representation of redox cerium oxide nanoparticles. (1) Nanoceria 
was synthesized using alkaline precipitation method with PAA coating on its surface. (3) 
Propargylated NPs were synthesized using carbodiimide chemistry. Click chemistry has 
been used to functionalize the NPs with folic acid (4 and 5). Co-encapsulation of dye and 
chemotherapeutic drugs was done using solvent diffusion method (2, 4 and 5) to produce 





Figure 3: Characterization of functional nanoceria. (A and B) Average zeta potential 
(surface charge) of NC-COOH and NC-FOL was found to be -25.6 and -11.8 mV by DLS. 
(C) UV-Visible absorption spectra at 360 nm and (D) Fluorescence emission spectra at 
460 nm confirms the successful conjugation of folic acid on the surface of the NPs. (E) 
Presence of folic acid and DiI dye is confirmed by the UV absorption bands at 360 nm 
and 585 nm. (F) Fluorescence emission spectra of NPs encapsulated with DiI dye (λmax 
= 600 nm). 
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Drug release profiles: 
To verify the drug release kinetics of our nanoparticle in the presence of appropriate 
external environment, we determined the release profile of the drug and dye from the 
nanocarrier at two different pH conditions (acidic – 6.0 and physiological – 7.4) in vitro. 
According to hypothesis, the polymer coatings of nanoparticles are disrupted in acidic 
environment thereby releasing the cargos. Time dependent study of released cargos was 
determined using the plate reader.  
 
Figure 4: Controlled drug release profiles of NC-LSL-FOL using dialysis method. (A) 
Controlled release of LSL drug from encapsulated NPs with time in acidic pH (pH 6.0) 
was observed and about 80% of drug is released within 6 h of time. However, minimal 
release was seen at normal pH (pH 7.4). (B) Similarly, release of DiI dye in acidic pH was 
studied at (λem = 585 nm) using UV where the absorption maxima increase with release 
of time. However, there is no or minimal release of drug and dye at normal pH conditions. 
In the cumulative release of drug at pH 6.0 as shown in Figure 4A, a burst release of 
drug (80%) was observed within 6 h and then the release was stable. Whereas, the dye 
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release was slower when compared to that of the drug. Maximum amount of dye was 
released in 12 h of time (60%) and then remained stable (Figure 4B). In contrast, at 
physiological pH, no detectable release of drug or dye was observed. These results 
confirm that our nanoparticles release the cargos within the acidic environment of tumor 
cells and are stable at normal pH.  
Cell viability assay (MTT Assay): 
In an attempt to assess the therapeutic efficacy of nanoceria loaded with cargos, a series 
of cytotoxic experiments were conducted with different functional nanoparticles on two 
different cell lines, A549 (folate-positive) and CHO (folate-negative) cells in a time 
dependent manner. Briefly, cells (2500 cells/well) were seeded in 96-well plate and 
incubated with various functional folate conjugated nanoceria preparations (35 µL, 1.0 X 
10-3 mol) at 37°C followed by incubation of MTT. The data was collected at regular 
intervals of time. Interestingly, upon incubation with LSL alone more than 40 % of cells 
were found to be dead after 24 h of incubation. This was synergized by GT and both the 
drugs in combination (NC-LSL-GT-FOL, 1.0 X 10-3 mol) showed more than 80% of cell 
death within 24 h of incubation and when continued to 48 h, it showed 90% of cell death 
(Figure 5A). However, nanoceria by itself without drugs showed minimal toxicity to both 
the cancer cells and normal cells, indicating the biocompatibility of our redox-based drug 
delivery system. No significant cytotoxicity was observed when CHO cells were incubated 
with drug loaded folate nanoceria (Figure 5B) due to the absence of folate receptors. The 
main characteristic of our nanoplatform is to minimize the side effects and increase the 
uptake of drugs via active targeting by using folate conjugated nanoceria. From the 
results, it is evident that LSL activity is accelerated by GT as result of synergistic effect. 
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Thus, the targeted delivery of our functional nanoceria encapsulated with LSL and GT 
would provide an excellent therapy for potentially addressing the MDR effect in the 
treatment of undruggable NSCLC and other tumors. 
 
Figure 5: Determination of cytotoxicity of formulated nanoceria using MTT assay. (A) 
More than 80% of cells were dead within 24 h when incubated combinational drugs 
carrying nanoceria, whereas only 40% toxicity was observed with delivery of single drug. 
(B) On the other hand, minimal toxicity was observed when functional nanoceria was 
incubated with CHO cells (FR -), suggesting targeted delivery of drugs specifically to 
tumor site.  
Confocal Laser-Scanning Microscopy: 
To shed light on dye release monitoring in living cells, we recorded a set of laser scanning 
fluorescent microscopic images to visualize the intracellular dye and drug release. During 
the imaging process, to avoid heat effect-induced cell death the exposure time of laser 
was given shorter than 400 ms. We hypothesized that folate conjugated nanoceria would 
target tumors overexpressing folate receptors and gets internalized, minimizing the 
toxicity to healthy cells. When carboxylated nanoceria encapsulated with combinational 
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drugs (NC-LSL-GT-COOH, 1.0 X 10-3 mol, Figure 6A-6D) was incubated in A549 cells, 
there was no or minimal internalization. This is due to the lack of folate ligands on the 
surface of our nanoparticle which could not target folate receptors. According to our 
hypothesis, folate conjugated nanoceria will gets internalized in the folate expressing 
tumors. To validate this, A549 cells were incubated with folate nanoceria encapsulated 
with DiI dye and interestingly, internalization of nanoceria with the release of dye was 
observed as the cytoplasm was found to be red (Figure 6E-6H). To further demonstrate 
the folate receptor-mediated internalizations, A549 cells were incubated with LSL and GT 
loaded folate nanoceria (1.0 X 10-3 mol) huge change in cellular morphology was 
observed where the cytoplasm is ruptured and the nucleus is disorganized (Figure 6I-
6L). These results signify the local targeting and delivery of drugs effectively to cancer 
cells. When CHO cells were incubated with drugs encapsulating folate nanoceria, there 
was no or minimal internalization due to the lack of folate receptors on the surface of CHO 
cells (Healthy cells). This confirms the tumor-targeting ability of our functional nanoceria, 
while minimizing the toxicity to healthy cells. (Figure 6M-6P). Taken together, these 
results indicate the possibility of our designed nanoplatform to be used for targeted 




Figure 6: Representative fluorescence microscopic images of the in vitro cellular imaging 
and drug delivery experiments. No or minimal internalization of carboxylated NPs loaded 
with combination of drugs was observed in A549 cells due to absence of folic acid on 
surface of NPs (A-D). Effective internalization of folate NPs with no drugs was observed 
due to folate receptor-mediated endocytosis (E-F). However, when drugs-loaded folate 
nanoceria was incubated with A549 cells, substantial amount of cell death was observed 
(I-L). In contrast, minimal internalization of folate NPs was observed in CHO cells due to 
the absence of folate receptors on the surface of the CHO cells (M-P), indicating the 





Cytosolic ROS detection assay: 
A newer approach to achieve better anticancer therapy is to enhance ROS levels 
selectively in the cancer cells. The generation of ROS in the cell is determined by 
Dihydroethidium (DHE), a fluorescent dye which is oxidized to 2-hydroxyethidium in the 
presence of reactive oxygen species and gives red fluorescence after intercalating within 
the nuclei. Previous studies have shown ROS generation via HDAC inhibition as one of 
the mechanisms by which LSL exerts its antitumor activity. To determine the GT 
synergizes the ROS production of LSL, A549 cells were treated with combinational drugs, 
LSL and GT carrying folate nanoceria (5, 1.0 X 10-3 mol, Scheme 1). Briefly, A549 cells 
were seeded into 12-well plates (10000 cells/well) and when confluent, they are incubated 
with different functional nanocarriers: (1) folate nanoceria without drug (NC-FOL), (2) 
folate nanoceria with GT alone (NC-GT-FOL), (3) folate nanoceria with only LSL (NC-
LSL-FOL), (4) folate nanoceria with combinational drugs (NC-LSL-GT-FOL). After 6 h of 
treatment of drugs, the cells were washed and stained with cytosolic cell permeable probe 
dihydroethidium (DHE) for 30 min. As expected, the cells treated with folate nanoceria 
showed minimal fluorescence due to limited ROS stress (Figure 7A-i). Folate nanoceria 
with GT showed significant amount of fluorescence indicating the stress induced by ROS 
(Figure 7C-iii). In contrast, folate nanoceria encapsulated with only LSL showed elevated 
ROS levels as observed by higher fluorescence intensity (Figure 7B-ii). This is due to 
the cytotoxicity of LSL via HDAC inhibition pathway. When incubated with combinational 
drugs (NC-LSL-GT-FOL, 1.0 X 10-3 mol, 5, Scheme 1), there was huge rise in the levels 
of ROS Figure 7D-iv and this validates that the synergistic effect of GT improves 




Figure 7: Determination of ROS generation. Incubation of A549 cells with different 
nanocarriers shows the increase in fluorescence due to increased ROS levels. Due to the 
effect of synergism, ROS levels are increased in order of folate nanoceria to folate 
nanoceria with combinational drugs. 
In addition, quantification of ROS was determined by calculating the numerical data of 
fluorescence intensities from each fluorescence microscopic images using commercial 






Figure 8: Quantification of ROS: Amount of ROS generation was quantified directly from 
the microscopic images using Image J software. Results showed relatively higher 
fluorescence from A549 cells treated with combinational drugs due to the presence of 
increased amount of ROS. 
Apoptosis and necrosis detection assay: 
Increased ROS production is incriminated in apoptosis and has been reported as an early 
event which is followed by necrosis. Having known that our functional nanoceria produces 
ROS, next we want to further elucidate the correlation between ROS generation and 
apoptosis induction. In these experiments, A549 cells were exposed to various 
nanocarriers, NC-FOL, NC-GT-FOL, NC-LSL-FOL and NC-LSL-GT-FOL (1.0 X 10-3 mol) 
for 24 h. In our study, the apoptotic and necrotic cells were distinguished on the basis of 
their cell integrity and morphology by using fluorescence microscope. Upon staining with 
Annexin V-FITC and Ethidium homodimer III, the apoptotic and necrotic cells exhibited 
green and red fluorescence respectively. This is due to the various morphological and 
biochemical changes occurring the tumor cells including the translocation of 
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phosphatidylserine (PS) due to apoptosis. As demonstrated in the Figure 9A, folate 
nanoceria shows fewer apoptotic cells which is related to the antioxidant nature of 
nanoceria. Annexin V and ethidium homodimer staining pattern determines that NC-LSL-
FOL leads to early and late apoptosis (major green spots for apoptotic cells and fewer 
red spots for necrotic cells, (Figure 9C). Upon treatment with combinational drugs, 
increased apoptotic and necrotic cells were seen (Figure 9D) thus confirming that 
treatment of GT accelerates the LSL apoptosis induction leading to extensive loss in 
membrane integrity, eventually leading to cell death via necrosis. Taken together, our 
results suggest that combination of LSL and GT might provide better anti-tumor effect 
through synergistic effect in the treatment of NSCLC. In addition, the development of 
functional nanoceria encapsulated with combinational drugs would be an ideal drug 




Figure 9: Detection of apoptotic and necrotic cell death by fluorescence microcopy using 
annexin V-FITC and ethidium homodimer III. (A) Healthy cells emitted limited 
fluorescence representing early apoptosis. (B & C) When incubated with single drugs, 
green fluorescence was emitted by apoptotic cells (D) Combinational drugs exhibited both 
green and red fluorescence due to late apoptotic and necrotic cells. (a, b, c and d) 




Metastasis is the deadliest aspect of cancer and remains the principal cause of death 
despite of research aimed at restricting tumor growth. One such case is with K-RAS driven 
NSCLC. To assess whether our combinational drugs carrying nanoceria is capable of 
inhibiting the migration of tumor cells; we performed transwell migration assays. Briefly, 
in these experiments, A549 cells were serum starved and treated with functional 
nanoparticles (1.0 X 10-3 mol) and incubated for 24 h by seeding in upper invasion 
chamber. When incubated with only nanoceria (no drugs, NC-FOL) our results showed 
that the cells migrated from invasion chamber to the lower feeder tray containing 10% 
FBS (CTRL, Figure 10). However, upon incubation with combinational drugs, the 
migration ability of cells has decreased considerably as noticed by the change in 
fluorescence intensity (Figure 10). Collectively, our results demonstrated that the 
combinational drug therapy of LSL and GT along with the functional nanoceria might play 






Figure 10: Determination of anti-migratory effect of highly metastatic lung cancer cells 
via migration assay. As represented, control (no drugs, red lines) showed significant 
migration of cells. Whereas, nanoceria with combinational drug (black lines) had showed 
minimal migration as the drugs are capable of inhibiting the metastatic nature of the cells. 
HDAC Inhibition assay: 
For the detection of HDAC inhibition activity of lactonic sophorolipids, we performed the 
fluorescent HDAC inhibition assay according to manufacturer protocol. As presented 
(Figure 11), positive control (HeLa extract, has HDAC activity) has shown high 
fluorescence intensity as the substrate containing acetylated lysine residue is 
deacetylated by the HDAC enzyme. In contrast, negative control, Trichostatin had shown 
minimum fluorescence as the HDAC is completely inhibited and therefore the acetylated 
residue is not deacetylated. When incubated with our functional nanoparticles (NC-
LSL/GT-FOL and NC-LSL-FOL), significant fluorescence was seen as the acetylated 
HDAC substrate is not deacetylated due to the HDAC inhibition. As a result, there is a 
reduction in fluorophore intensity in the sample wells (low fluorescence intensity), when 
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compared to positive control thereby confirming that lactonic sophorolipids follows the 
HDAC inhibition pathway leading to the apoptosis. However, ganetespib, the 
combinational drug of LSL in our study is showing a modest synergistic effect during this 
mechanism. 
 
Figure 11: Assessment of inhibition of histone deacetylase (HDAC) by lactonic 
sophorolipids (LSL) in comparison with positive and negative controls. As depicted, 
positive control shows enormous inhibition and the drugs had significant effect on HDAC 






























Cerium nitrate hexahydrate (Ce(NO3)3), Polyacrylic acid (PAA), Ammonium hydroxide 
(NH4OH), Folic acid, N-hydroxysuccinimide (NHS), 2(N—morpholino) ethanesulfonic acid 
(MES) sodium salt, Tetrahydron furan, acetonitrile, Sodium azide, Ethanol, Isopropanol 
and Propargylamine (PA) were purchased from Acros organics and used without further 
purification. Near infrared dye (DiI-D282) was obtained from Life technologies. N, N’-
dimethyl formamide (DMF) and Dihydroethidium (DHE) dye was purchased from Science 
lab and Cayman chemicals respectively. N, N’-dimethyl sulfoxide (DMSO), 3-(4, 5-
dimethylthiazol-2-yl) - 2, 5-diphenyltetrazolium bromide (MTT) and (1-ethyl-3-[3-
(dimethylamino) propyl] carbodiimide hydrochloride) (EDC) were obtained from Sigma 
Aldrich and used as received. 4, 6-diamidino-2-phenylindole (DAPI-D1306) was 
purchased from Invitrogen. Dialysis membrane were received from spectrum 
laboratories. Paraformaldehyde and H2O2 were received from electron microscopy 
sciences. Fetal bovine serum (FBS) and 5X Annexin binding buffer were purchased from 
BD biosciences, whereas Gantespib, Isopropyl alcohol, Apoptosis and Necrosis 
quantification kit (FITC-Annexin V, Ethidium homodimer III) were obtained from Biotium. 
Migration assay kit and HDAC inhibition fluorometric assay kit was obtained from Millipore 
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and Biovision respectively. The human lung carcinoma cell line A549 cells (NSCLC) and 
Chinese hamster cells (CHO) were obtained from ATCC (U.S.A). Dulbecco’s modified 
eagle (DMEM) medium and Kaighn’s modification of Ham’s F12K cell culture medium 
were purchased from Corning. 
Synthesis of Poly (acrylic acid)-Coated Nanoceria (NC-COOH) (1): 
To synthesize PAA coated nanoceria, previously reported alkaline-based precipitation 
method was followed, where the cerium oxide nanoparticles were precipitated from a 
solution of ammonium hydroxide containing cerium salt and PAA. The synthetic 
procedure involves the preparation of two different solutions – Solution A: cerium nitrate 
(0.9 g) in 2.5 ml of DI water, Solution B: PAA (0.9 g) in 10 ml of DI water. 30 ml of 
ammonium hydroxide was taken in a beaker and was stirred at room temperature and 
solution A was added to it followed by addition of solution B. We can notice the color 
change from colorless to brown within 5 min of stirring and became deep yellow after 24 
h, indicating the preparation of stable nanoceria. The reaction mixture was centrifuged 
thrice at 3000, 3500 and 4000 rpm for 15, 20 and 20 min respectively to obtain smaller 
size nanoparticles. The solution was further purified by dialysis technique using a dialysis 
bag of molecular weight (MWCO) 6-8K against DI water and finally with phosphate buffer 
saline (PBS, pH = 7.4) to remove ammonium hydroxide by selective and passive diffusion 
through a semi-permeable membrane (dialysis tubing) (Scheme 1). The purified 
nanoceria was stored at 4°C for further characterizations. Successful coating of PAA on 
nanoceria was characterized by Fourier Transform Infra-Red (FT-IR) spectroscopy. 




Synthesis of propargylated or alkynated NC (3); Carbodiimide chemistry: 
Propargylated NC was synthesized by adding freshly prepared EDC (15 X 10-3 mol) 
solution followed by addition of NHS (15 X 10-3 mol) in 200 µL of MES buffer (0.1 M), pH 
= 6.0, after brief mixing. The reaction mixture was incubated for an additional 3 min at 
room temperature and then propargylamine (15 X 10-3 mol) dissolved in DMSO was 
added dropwise and mixed. The reaction was continued for 4-6 h for completion at room 
temperature. The resultant propargylated NC was purified against PBS (pH = 7.4) using 
the dialysis method to remove the unreacted reagents from the solution. 
Synthesis of Aminopropyl azide:  
Aminopropylazide was synthesized by reacting chloropropyl amine (7.0 g, 75.26 mmol) 
and sodium azide (14.23 g, 225.81 mmol) in 40 mL of distilled water. The reaction was 
carried out at 800 C for 20 h. The reaction mixture is then concentrated using rotary 
evaporator at high vacuum. 2 g of KOH was added and the product was extracted using 
diethyl ether. Subsequently, the reaction mixture was dried over anhydrous sodium 
sulfate and concentrated. Purification of the product was done by column chromatography 
using 4% ethyl acetate in petroleum ether. 
Synthesis of folate-azide; Carbodiimide chemistry: 
To the solution of folic acid (0.05 g, 0.12 mmol) in 7 mL phosphate buffer saline (PBS, pH 
7.4), freshly prepared EDC (0.021 g, 0.11 mmol) followed by NHS (0.013 g, 0.11mmol) in 
0.25 mL MES buffer (pH = 5.0) were added and then incubated at room temperature for 
about 3. To this resulting mixture, add dropwise aminopropyl azide (0.0014 g, 0.11 mmol) 
in 0.5 mL of MES (pH = 5.0) and incubate it for 3 h at room temperature. The carboxyl 
groups of folic acid react with azide and forms azide-functionalized folic acid. 
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Synthesis of folate conjugated NC (NC-FOL) (4 and 5) using “click chemistry”: 
To the solution of alkynated NC suspension (2 mL, 1.5 X 10-3 mmol) in bicarbonate buffer 
(pH 7.4) and folate-azide (FoL  ̴N3, 2 X 10-2 mol), catalytic amount of CuI catalyst (1 X 
10-3 mmol) in DMF was added and incubated on table mixer for overnight at room 
temperature. The resulting folate conjugated NC was purified by dialysis to remove 
unreacted materials. The purified product was stored at 4°C for further characterizations.  
Encapsulation of DiI dye (2 and 4): Modified solvent diffusion method: 
For dye encapsulation, solvent diffusion method has been used. To 1 mL of nanoceria 
(NC-COOH or NC-FOL) suspension, near infrared DiI dye (1 µL of 1 µM DiI dye in 100 
µL of DMSO) was added dropwise with continuous stirring at 1500 rpm at room 
temperature. The solution was incubated on table-mixer for 3 h and was dialyzed against 
PBS (pH = 7.4) for 2 h to remove free dye from the solution. Successful encapsulation of 
DiI was further confirmed using UV-Vis and fluorescence spectrophotometric analyses. 
The purified dye-labeled nanoceria was stored at 4°C for further studies. 
Coencapsulation of Lactonic sophorolipids (LSL), Ganetespib (GT):  
Using a similar solvent diffusion method, drug or combination of drugs and dye were co-
encapsulated. Briefly, a solution of either LSL and DiI or LSL-GT-DiI or GT and DiI (2 µM 
of the drug in 100 µL DMSO) was added dropwise to 2 mL of vortexing NC-FOL 
suspension, followed by overnight incubation. The drug-encapsulating functional NC-FOL 
were dialyzed against PBS (pH = 7.4) for 3 h. The purified suspension was stored at 4°C 





Characterizations of Functional Nanoceria: 
Fourier transform infrared spectroscopy (FTIR): 
To verify the surface functionalities of our synthesized nanoceria, we performed FTIR 
studies using Perkin-Elmer’s Spectrum. PAA coated nanoceria was air dried and the 
powdered crystals were collected. FT-IR spectra of dried PAA coated nanoceria and PAA 
polymer was recorded and compared to confirm the successful coating of PAA on the 
synthesized nanoparticles. 
Dynamic light scattering (DLS): 
The average size distribution and surface charge of the functional nanoceria were 
obtained using dynamic light scattering technique. Malvern’s nano-ZS90 zeta sizer was 
used for DLS studies.1 ml of NC-COOH was taken in the cuvette and measured for size 
using standard procedure set in Malvern Zetasizer. For measuring zeta potential, the 
sample was diluted with DI water and is carefully loaded in electrode without air bubble 
and the zeta potential is measured and recorded. 
Spectrophotometric analysis: 
UV-vis and fluorescence spectroscopic studies of functional nanoceria were recorded 
using TECAN’s infinite M200 PRO high throughput plate reader to confirm the successful 
conjugation of folic acid ligands on the surface of nanoceria for targeted drug delivery. 
Similarly, the studies were also performed for the presence of DiI dye in the nanoparticles 
for optical imaging. The procedure involves the addition of 75 µL of suspension in Thermo 
Fisher 96 well plate and measuring the absorbance and fluorescence at 300-800 nm and 




In vitro cell studies: 
Cell Culture: 
Human lung cancer cells (A549 cells) and Chinese Hamster ovarian cells (CHO cells – 
normal cells) were obtained from ATCC. A549 cells were maintained in a 10% FBS-
containing DMEM medium supplemented with 1% antibiotic, whereas, CHO cells were 
propagated in 10% FBS containing Ham’s F12K media containing 1% penicillin-
streptomycin antibiotic. Cells were grown under 5% CO2 atmosphere at 37° C in a 
humidified incubator. 
Cell viability assay (MTT Assay): 
To determine the time-dependent cytotoxicity, two different cell lines, lung carcinoma 
(A549 cells) and Chinese hamster ovarian cells (CHO cells) were used. Cells were 
seeded in 96-well plates at a density of 3500 cells per well and treated with various 
functional folate conjugated nanoceria (1.0 X 10-3 mol) and incubated at 37° C for different 
time points. Each well was washed twice with PBS and then incubated with 30 µL of 5mM 
MTT solution. After 4-6 h of incubation, the resulting formazan crystals (purple color) were 
dissolved in acidic isopropanol (75 µL) and the absorbance was recorded at 570 nm using 
TECAN’s microplate reader. The assay was carried out in triplicates and the results are 
reported. 
Drug release profiles: 
The in vitro dye/drug release studies were carried out by using a dynamic dialysis 
technique at 37° C. Drug/dye-loaded nanoparticles were packed in a dialysis bag and 
suspended in 2 different environments of PBS (200 mL, pH 7.4 and 6). The amount of 
drug/dye molecules released from the nanoparticles into the PBS solution was 
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determined at regular intervals of time by taking 1 mL aliquots from the PBS solution and 
replacing the same with PBS solution. Fluorescence emission was measured at 585 nm 
for DiI dye. The concentration of dye released was calculated using standard calibration 
curve and the cumulative release versus time was calculated using the following equation: 
Cumulative release (%) = (dye released)t / (dye released)total X 100 
Where, (dye released)t is the amount of dye released at time t, and (dye 
released)total is the total dye present in the dye/drug encapsulated nanoparticles. 
Confocal Laser-Scanning Microscopy: 
Lung carcinoma cells (A549 cells) and Chinese Hamster Ovarian cells (CHO – Normal 
cells) were seeded into the culture dishes and grown overnight. Once the cells are 75% 
confluent, different functional drug loaded nanoparticles (NC-COOH, NC-DiI-FOL, NC-
LSL-GT-DiI-FOL, 1.0 X 10-3 mol) were treated to the cells and incubated at 37° C for 24 
h. The cells were washed thrice with 1X PBS (pH = 7.4) and were fixed with 4% 
formaldehyde solution for 15 min at room temperature. The cells were again washed with 
1X PBS before treating with DAPI dye (5mg/mL) for staining cell nuclei. The cells were 
then washed with 1X PBS and optical images were taken using fluorescence microscope 
(Olympus IX73) for cellular internalization of dyes and killing of cells. For the control 
experiment, CHO cells were treated with NC-LSL-GT-DiI-FOL (1.0 X 10-3 mol) and the 
results were shown. 
Cytosolic ROS detection assay: 
To know the mechanism of the killing process of cancerous cells, various assays were 
performed, of which, ROS is one among them. This assay determines the process of 
induction of stress to the cells by the generation of reactive oxygen species. A549 cells 
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were seeded in 12-well plates at a density of 10000 cells per well and treated with 
nanoparticles encapsulated with different drugs (1.0 X 10-3 mol) and incubated at 37° C. 
After 6 h of incubation, the cells were washed thrice with 1X PBS and stained with 20 µL 
of DHE fluorescent probe for about 30min at room temperature followed by washing the 
cells twice with 1X PBS. Subsequently, the cells were fixed with 1 mL of 
paraformaldehyde solution. After fixation, the cells were washed with 1X PBS, stored with 
2 mL PBS in each well and optical images were taken using fluorescence microscope. 
Quantification of ROS fluorescent images: 
Using ROS fluorescent images, the amount of ROS was quantified using commercial 
ImageJ software. Particular cell from each treated well was selected to get a stack of 
values for the area, integrated density, and mean fluorescence of background readings. 
The corrected total cell fluorescence (CTCF) for each well was calculated using the 
formula:  
CTCF = integrated density – (area of selected cell X mean fluorescence of 
background readings). 
Apoptosis and necrosis detection assay: 
For the assessment of apoptosis and necrosis, Annexin V-FITC and Ethidium homodimer 
III was used. This assay is based on the translocation of phosphatidylserine (PS) from 
the plasma membrane to the cell surface soon after the initiation of apoptosis. The 
translocated PS can be easily detected by a protein, Annexin V in conjugation with FITC 
which has the strong affinity for PS. Briefly, A549 cells were seeded in 12-well plates at 
a density of 10000 cells per well. After confluence, cells were treated with different 
preparations (NC-FOL, NC-LSL-FOL, NC-GT-FOL and NC-LSL-GT-FOL, 1.0 X 10-3 mol). 
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After 6 h of incubation, the cells were washed twice with 1X PBS and stained with two 
different dyes, 5 µL of FITC-annexin buffer and 5 µL of ethidium homodimer III and 
incubated for 15 min in the dark. Later the cells were washed twice with 1X binding buffer 
and fixed with 4% formaldehyde solution and the cells were covered with 1X binding 
buffer. Multiple fluorescence images were taken using two filters: green fluorescence 
represents apoptosis; red fluorescence indicates necrosis. 
Migration Assay: 
Cell migration is a multi-step process that plays an important role in the progression of 
cancer and other diseases. It is the movement of cells from one area to another in 
response to a chemical signal. Currently, determining the migratory and invasive capacity 
of tumor cells and elucidating their mechanisms is more important for cancer diagnosis 
and treatment. Herein Chemicon QCM 96-well cell migration assay kit from Millipore was 
used to evaluate the migration of cells in presence of functional nanoparticles in vitro. 
Experimental procedure involves the incubation of serum starved A549 cells for 24 h. 
Next, the cells were harvested and treated with the functional nanoparticles (NC-LSL/GT-
FOL).  Subsequently, the cells were seeded in invasion chamber of the migratory assay 
kit coated with collagen layer. The feeder tray contained 10% FBS media and the 
complete set up was incubated at 37° C for 24 h to allow the migration of cells. Later, the 
migratory cells were dislodged completely from the invasion chamber and placed on new 
feeder tray containing cell detachment buffer and incubated for 30 min. Finally, a diluted 
solution of CyQuant GR dye and cell lysis buffer was added to stain migratory cells and 




HDAC Inhibition Assay: 
Acetylation and deacetylation of histone proteins influence the gene expression by 
modulating the chromatin structure. Two enzymes, histone acetyltransferase (HAT) and 
histone deacetylase (HDAC) mediate the balance between acetylated and deacetylated 
states. HDAC has a wide spectrum of cellular functions including regulation of gene 
transcription, translocation of transcriptional factors and apoptosis by altering acetylation 
of various proteins. Several studies have shown that inhibiting HDAC in cancer cells leads 
to cell differentiation and reduced cell growth, making HDAC notable and attractive 
antitumor target for cancer therapy. 
HDAC fluorometric assay kit from Biovision was used to determine the HDAC inhibition 
ability of lactonic sophorolipids (LSL). The assay was performed according to 
manufacturer’s protocol. HeLa nuclear extract and Trichostatin A were used as positive 
and negative controls respectively. Briefly, A549 cells were seeded in 96-well microtiter 
plates (10000 cells/well) and after 80% confluence, the cells were treated with 
nanoparticles (NC-LSL/GT-FOL and NC-LSL-FOL) and incubated at 37° C for 24 h. 
Positive and negative controls were added along with HDAC assay buffer and the reaction 
was initiated by adding HDAC fluorometric substrate and incubating for 30 min or longer 
as desired by the drugs. Later, the HDAC lysine developer was added to stop the reaction 






















In conclusion, we have successfully synthesized functional nanoceria with 
combinational drugs as a drug vehicle for the treatment of K-RAS driven NSCLC. 
Targeted delivery is achieved through folate conjugation of nanoceria and the 
synergistic effect of combinational drugs was observed. Encapsulation studies and 
enhanced stability confirmed excellent drug payload with high therapeutic efficacy 
and reduced toxicity. More than 90% of cells were dead when incubated with 
combinational drugs as reflected by combinational therapy. Results indicated that 
GT synergizes the activity of LSL, as confirmed by MTT and ROS assays. 
Apoptosis and necrosis assays further proved the synergistic effect of drugs by 
increased apoptotic and necrotic cells. In addition, migration assay validated the 
important role of combinational drugs in preventing lung cancer metastasis. 
Therefore, our study of delivering combinational drugs using functional nanoceria 
provides clinically actionable information that could impact treatment decisions for 
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